Phase 4 N=52 Early Sodium Intake in Preterm Newborns
Hyponatremia · Premature
Primary: Hyponatremia — 6; 1 Participants — p=0.71
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=167 Maintenance Intravenous Fluids in Children
Hyponatremia
Primary: Incidence of Hyponatremia (Defined as Serum Sodium Less Than 130 mmol/L) — 1; 2; 8 participants — p=<0.05
Phase 3 N=161 Use of Isotonic Solutions Versus Hypotonic Solutions for Preventing Hospital Acquired Hyponatremia
Hyponatremia
Primary: Hospital Acquired Hyponatremia — 10; 11; 1 participants
Phase 3 N=16 A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH
Syndrome of Inappropriate Antidiuretic Hormone Secretion
Primary: Percentage of Subjects With Normalized Serum Sodium Concentration on the Day After Final IMP Administration — 43.8; 80; 80; 85.7 percentage of participants
Phase 4 N=33 Aquaresis Utility for Hyponatremic Acute Heart Failure Study
Heart Failure
Primary: Median Urine Output at 24 Hours Post Randomization — 2910; 3150 mL
Phase 4 N=48 Tolvaptan in Hyponatremic Cancer Patients
Advanced Cancers
Primary: Participants Whose Serum Sodium Concentration Corrected to at Least 135 mEq/L on Day 14 — 16; 1 participants
N/A N=12 Central Sodium Sensing: Implications for Blood Pressure Regulation
Salt Sensitivity of Blood Pressure
Primary: Functional Connectivity Between the Subfornical Organ and Organum Vasculosum of the Lamina Terminalis (Z-score) — 0.258490; 0.359145; 0.207372; 0.169055 z-score
Phase 3 N=78 Variation in Natremia Using Two Different Maintenance Intravenous Fluids in Postsurgical Hospitalized Children
Hyponatremia
Primary: Change in Sodium Levels — 139.9; 138.1; 138.1; 138.2 mEq/L — p=0.030
N/A N=139 Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients
Intra-dialytic Hypotension
Primary: Change in Intra-dialytic Decline in Systolic Blood Pressure — 26; 23 mm Hg
Phase 3 N=50 Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
Hyponatremia
Primary: Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation. — 126.03; 126.39; 125.55; 130.4 mEq/L — p=0.028
Phase 4 N=121 A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
Hyponatremia · Euvolemia · Hypervolemia
Primary: Number and Severity of Infusion Site Reactions (ISRs) Using a Modified ISR Reporting Scale for Phlebitis and Infiltration in Patients Treated With Dose Regimen 1 and…
Phase 3 N=111 International, Multicenter, Study of One-year, Open-label, Titrated Oral Tolvaptan Tablet Administration in Patients With Chronic Hyponatremia
Hyponatremia
Primary: Participants With Adverse Events (AEs) — 105; 76; 73; 19 participants
Phase 4 N=90 Physiologic Approach to Sodium Supplementation in Premature Infants
Postnatal Growth Disorder
Primary: Change in Somatic Growth (Weight) — 0.04; 0.16 score on a scale — p=0.162
Phase 3 N=57 Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients
Hyponatremia
Primary: Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores) — 0.20; 0.39 Z-score — p=0.08
Phase 2 N=59 Tissue Sodium in Pre-hypertensive Patients
Hypertension
Primary: Change in Tissue Sodium Concentration Measured Using Sodium Magnetic Resonance Imaging (NaMRI) — -0.202; 0.430; -1.745; -0.407 mmol/L
Phase 3 N=258 Hypotonic Versus Isotonic Parenteral (HIP) Fluid Trial
Hyponatremia · Hypernatremia
Primary: Hospital Acquired Acute Plasma Sodium Derangements (Hypo- or Hypernatremia)
N/A N=310 Pragmatic Urinary Sodium-based Treatment algoritHm in Acute Heart Failure
Heart Failure Acute
Primary: Total Natriuresis After 24 Hours — 409; 345 mmol
N/A N=70 An Observational Study to Describe the Adherence to the SEOM Algorithm for the Treatment of Hyponatraemia in Spain
Hyponatremia · Syndrome of Inappropriate ADH (SIADH) Secretion
Primary: Number of Patients Managed According to the SEOM Algorithm (as a Result Adherence to the Algorithm Will be the % of These Patients Among the Total Number of Patients)…
N/A N=38 Dietary Salt in Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: Plasma Volume — 2805; 3032; 2362; 2633 mL
Phase 2 N=6 Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access
Stroke · Intracranial Hypotension · Cerebral Edema
Primary: Number of Subjects With Tissue Damage — 0 Participants
Phase 3 N=301 Sodium Bicarbonate for Prevention of Contrast-Induced Nephropathy
Renal Failure
Primary: Contrast-induced Nephropathy — 6.1; 6.0 percentage of contrast nephropaty
Phase 2 N=32 Sodium Excretion of LCZ696 in Patients With Hypertension; Heart Failure and Healthy Volunteers
Hypertension
Primary: 24-hour Urinary Sodium Excretion — 220.58; 198.73; 177.40; 146.18 mmol/24 hours
Phase 2 N=30 A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
Primary: Maximal Increase From Baseline in Serum Sodium Concentration Following Tolvaptan Administration. — 3.6; 5.3; 7.9 mmol/L
Phase 2 N=44 Hypertonic Saline as Therapy for Pediatric Concussion
Pain
Primary: Change in Pain — 1.14; 3.5 units on a scale
N/A N=66 0.9% NaCl/Dextrose 5% vs 0.45% NaCl/Dextrose 5% as Maintenance Intravenous Fluids in Critically Ill Children
Hyponatremia
Primary: Serum Sodium Levels in Both Groups — 137.8; 140.0 mEq/L — p=0.04
N/A N=30 Buoy Electrolyte Study on Hydration Status of Active Men and Women
Dehydration · Electrolyte Imbalance · Electrolyte Depletion
Primary: Net Fluid Balance — 0.28; 0.05; 0.03 Liter
Phase 4 N=107 Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
Acute Heart Failure · Diuretics Drug Reactions
Primary: Mortality, Days in Hospital & Decongestion — 54.68; 44.16 % wins — p=0.357
N/A N=38 Dietary Sodium's Effect on Urinary Sodium and Dopamine Excretion in Patients With Postural Tachycardia Syndrome
Postural Orthostatic Tachycardia Syndrome
Primary: 24hr Urinary Sodium — 16.8; 280; 14.7; 245 milliequivalents
N/A N=100 An Observational Study on Real-world Use and Outcomes of Patients Treated With Tolvaptan for Hyponatraemia Due to SIADH
Hyponatremia · Syndrome of Inappropriate ADH (SIADH) Secretion
Primary: Change in Sodium Levels From Start of Treatment With Tolvaptan Until Hospital Discharge — 10.3 mmol/L
N/A N=27 Effect of Dietary Sodium Intake on Vascular Endothelium
Postural Tachycardia Syndrome (POTS)
Primary: FMD (% Change) — 12.75; 11.65; 11.43; 12.75 percentage of change